Review on monoclonal antibodies – Manufacturing aspects, tactics, and future prospects (Record no. 17229)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220730095540.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 220730b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 17397 |
| Author | Hariharan, M. |
| 245 ## - TITLE STATEMENT | |
| Title | Review on monoclonal antibodies – Manufacturing aspects, tactics, and future prospects |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.16 (2), Apr-Jun |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mandsaur |
| Name of publisher, distributor, etc. | BRNSS Publication Hub. |
| Year | 2022 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 143-151p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Since 1940, the researches related to antibodies have acknowledged beneficial understanding of the antibody formation, its structure and diversity but the experimentation in Hybridoma technology in 1975 instigated the interest in clinical application of monoclonal antibodies. Monoclonal antibodies are emerging pharmaceutical products, used in the treatment of cancer, allergies, auto-immune disease, and inflammation. Although a potent biologic, it has obstacles in regulatory approval process and its approval has been hindered due to a lack of manufacturing consistency or the implementation of manufacturing improvements late in the product development process. The major drawback is not being able to preserve the efficacy, safety, and promote industrialization of the product. This review predominantly emphasizes the complications that underlie in the development of monoclonal antibodies such as its instabilities, determines conceptual actions such as approaches for stabilization, and explains the problems and future prospects of monoclonal antibody therapy and alternative form of antibody delivery. The development of stable formulations and effective clinical implementation of monoclonal antibodies can be used for targeted drug delivery methods in the near future. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4639 |
| Topical term or geographic name entry element | PHARMACEUTICS |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 17400 |
| Co-Author | Nithya, R. |
| 773 0# - HOST ITEM ENTRY | |
| Title | International journal of green pharmacy |
| International Standard Serial Number | 0973-8258 |
| Place, publisher, and date of publication | Mandsaur B.R. Nahata Smriti Sansthan |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://doi.org/10.22377/ijgp.v16i2.3248 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection code | Permanent Location | Current Location | Shelving location | Date acquired | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | School of Pharmacy | School of Pharmacy | Archieval Section | 2022-07-30 | 2022-1231 | 2022-07-30 | 2022-07-30 | Articles Abstract Database |